Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: Role of hyporesponsiveness and anergy

被引:111
作者
Borkow, G
Bentwich, Z
机构
[1] Hebrew Univ Jerusalem, Fac Agr, IL-76100 Rehovot, Israel
[2] Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91010 Jerusalem, Israel
关键词
D O I
10.1128/CMR.17.4.1012-1030.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Chronic immune activation is one of the hallmarks of human immunodeficiency virus (HIV) infection. It is present also, with very similar characteristics, in very large human populations infested with helminthic infections. We have tried to review the studies addressing the changes in the immune profiles and responses of hosts infected with either one of these two chronic infections. Not surprisingly, several of the immune derangements and impairments seen in HIV infection, and considered by many to be the "specific" effects of HIV, can be found in helminth-infected but HIV-noninfected individuals and can thus be accounted for by the chronic immune activation itself. A less appreciated element in chronic immune activation is the immune suppression and anergy which it may generate. Both HIV and helminth infections represent this aspect in a very wide and illustrative way. Different degrees of anew and immune hyporesponsiveness are present in these infections and probably have far-reaching effects on the ability of the host to cope with these and other infections. Furthermore, they may have important practical implications, especially with regard to protective vaccinations against AIDS, for populations chronically infected with helminths and therefore widely anergic. The current knowledge of the mechanisms responsible for the generation of anergy by chronic immune activation is thoroughly reviewed.
引用
收藏
页码:1012 / +
页数:20
相关论文
共 276 条
[31]  
Borkow G, 2000, B WORLD HEALTH ORGAN, V78, P1368
[32]   Host background immunity and human immunodeficiency virus protective vaccines, a major consideration for vaccine efficacy in Africa and in developing countries [J].
Borkow, G ;
Bentwich, Z .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2002, 9 (03) :505-507
[33]  
Borkow G, 2001, SCAND J INFECT DIS, V33, P568, DOI 10.1080/00365540110026656
[34]   Chronic immune activation associated with intestinal helminth infections results in impaired signal transduction and anergy [J].
Borkow, G ;
Leng, QB ;
Weisman, Z ;
Stein, M ;
Galai, N ;
Kalinkovich, A ;
Bentwich, Z .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (08) :1053-1060
[35]   Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus [J].
Borrow, P ;
Lewicki, H ;
Wei, XP ;
Horwitz, MS ;
Peffer, N ;
Meyers, H ;
Nelson, JA ;
Gairin, JE ;
Hahn, BH ;
Oldstone, MBA ;
Shaw, GM .
NATURE MEDICINE, 1997, 3 (02) :205-211
[36]   CD28 expression in T cell aging and human longevity [J].
Boucher, N ;
Dufeu-Duchesne, T ;
Vicaut, E ;
Farge, D ;
Effros, RB ;
Schachter, F .
EXPERIMENTAL GERONTOLOGY, 1998, 33 (03) :267-282
[37]   Maintenance of human T cell anergy: Blocking of IL-2 gene transcription by activated Rap1 [J].
Boussiotis, VA ;
Freeman, GJ ;
Berezovskaya, A ;
Barber, DL ;
Nadler, LM .
SCIENCE, 1997, 278 (5335) :124-128
[38]   The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response [J].
Boussiotis, VA ;
Freeman, GJ ;
Gribben, JG ;
Nadler, LM .
IMMUNOLOGICAL REVIEWS, 1996, 153 :5-26
[39]   In vivo protective anti-HIV immune responses in non-human primates through DNA immunization [J].
Boyer, JD ;
Wang, B ;
Ugen, KE ;
Agadjanyan, M ;
Javadian, A ;
Frost, P ;
Dang, KS ;
Carrano, RA ;
Ciccarelli, R ;
Coney, L ;
Williams, WV ;
Weiner, DB .
JOURNAL OF MEDICAL PRIMATOLOGY, 1996, 25 (03) :242-250
[40]   Towards an atlas of human helminth infection in sub-Saharan Africa: The use of geographical information systems (GIS) [J].
Brooker, S ;
Rowlands, M ;
Haller, L ;
Savioli, L ;
Bundy, DAP .
PARASITOLOGY TODAY, 2000, 16 (07) :303-307